Financial Performance - The company's revenue for Q1 2025 was ¥70,812,585.48, a decrease of 0.54% compared to ¥71,196,522.47 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥3,441,732.40, representing a decline of 129.32% from a profit of ¥11,738,167.74 in the previous year[5] - The basic and diluted earnings per share were both -¥0.02, down 128.57% from ¥0.07 in the previous year[5] - The company reported a net profit attributable to shareholders of -3.44 million RMB, a decrease of 129.32% compared to the same period last year[17] - Operating revenue for the first quarter of 2025 was 70.81 million RMB, a slight decrease of 0.54% year-on-year[17] - The company reported a net profit of -4,103,207.13, compared to a net profit of 11,469,685.34 in the previous period, indicating a significant decline[25] - Operating profit was -3,285,979.26, down from 13,315,867.35 in the previous period, reflecting a substantial decrease in operational performance[25] - The company recorded a total profit of -3,224,388.91, compared to 13,523,137.86 in the previous period, indicating a significant drop in overall profitability[25] Cash Flow - The net cash flow from operating activities was -¥15,921,419.26, a significant decrease of 23,162.65% compared to -¥68,441.98 in the same period last year[5] - The net cash flow from operating activities was -15.92 million RMB, a significant decline of 23,162.65% due to ongoing investments in new business segments[13] - Cash flow from operating activities showed a net outflow of -15,921,419.26, compared to a much smaller outflow of -68,441.98 in the previous period[27] - The company's cash and cash equivalents decreased to CNY 104,933,304.35 from CNY 159,100,886.52[20] - Total cash and cash equivalents at the end of the period were 104,933,304.35, down from 159,100,886.52 at the beginning of the period[28] - The company’s cash flow from financing activities showed a net inflow of 3,780,503.08, compared to an outflow of -284,803.09 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥920,505,782.32, a decrease of 1.36% from ¥933,166,569.41 at the end of the previous year[5] - The total assets of the company as of March 31, 2025, were CNY 920,505,782.32, down from CNY 933,166,569.41 at the beginning of the period[22] - The total liabilities decreased to CNY 154,394,324.06 from CNY 166,415,829.70[23] - The company's retained earnings decreased to CNY 159,732,407.59 from CNY 163,174,139.99[23] Investments and Acquisitions - The goodwill increased by 42.67% to ¥10,446,611.65 due to the acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd.[11] - The company expanded its medical health business segment, leading to a 55.09% increase in other receivables to ¥4,169,836.54[11] - The company reported a 114.99% increase in trading financial assets to ¥74,847,626.64, primarily due to new financial products purchased during the period[9] - The company incurred non-recurring gains of ¥1,214,492.33 during the reporting period[7] - The acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd. impacted profits by 11.06 million RMB, reflecting the costs associated with integrating new operations[17] - Hainan Wanmitang acquired 100% equity of Jiangxi Yuanqifud Pharmacy Chain Co., Ltd. and its 5 stores for CNY 500,000, enhancing its market presence through digital marketing strategies[19] - The company increased its investment in Noah Weikang by CNY 5.2 million, raising its ownership from 81% to 87.5%[19] Expenses - Management expenses increased by 61.07% to 12.67 million RMB due to the expansion into the healthcare and traditional Chinese medicine sectors[12] - Financial expenses rose by 154.43% to 0.24 million RMB, primarily due to increased financing costs from lease amortization[12] - Investment income decreased by 60.93% to 1.15 million RMB, attributed to reduced idle funds available for investment and lower financial market yields[12] - The company incurred a credit impairment loss of 135.42 thousand RMB, a decrease of 91.94% due to reduced bad debt write-offs[12] Sales and Market Performance - The company successfully won the national procurement for the product "Shengqi Jiangtang Pian," with a price reduction of approximately 30% compared to the original sales price, which is expected to expand sales in public hospitals and increase market share[18] - The registered capital of the subsidiary Hainan Wanmitang was increased from CNY 1 million to CNY 11 million, with the company holding a 51% stake post-increase[18] - The company received cash inflows from sales of 70,284,058.33, an increase from 67,764,781.90 in the previous period[27] Overall Financial Condition - The weighted average return on equity was -0.45%, down from 1.50% in the previous year[5] - The company's total comprehensive income attributable to the parent company was significantly lower, reflecting the overall decline in financial performance[26]

Financial Performance - The company's operating revenue for 2024 was ¥278,638,789.67, a decrease of 4.71% compared to ¥292,397,132.03 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥4,162,684.65, representing a significant decline of 87.57% from ¥33,501,697.88 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,532,207.68 in 2024, a decrease of 127.65% compared to ¥23,623,155.29 in 2023[18]. - The cash flow from operating activities for 2024 was ¥3,208,543.56, a turnaround from -¥12,799,223.82 in 2023, marking an increase of 125.07%[18]. - The total assets at the end of 2024 were ¥933,166,569.41, reflecting a growth of 9.07% from ¥855,535,468.09 at the end of 2023[18]. - The basic earnings per share for 2024 were ¥0.03, down 85.71% from ¥0.21 in 2023[18]. - In 2024, the company achieved operating revenue of 27,863.88 million yuan, a decrease of 1,375.83 million yuan or 4.71% year-on-year[41]. - The net profit attributable to shareholders was 416.27 million yuan, down 2,933.90 million yuan or 87.57% year-on-year; the net profit after deducting non-recurring gains and losses was -653.22 million yuan, a decrease of 3,015.54 million yuan or 127.65% year-on-year[41]. Dividend Distribution - The company plans to distribute a cash dividend of 0.50 RMB per 10 shares to all shareholders, based on a total of 160,000,000 shares[6]. - The annual cash dividend proposal for 2024 is set at 0.5 yuan per 10 shares, totaling 8,000,000 yuan (including tax) for 160,000,000 shares[135]. - The company has maintained a stable profit distribution policy, ensuring reasonable returns to investors[132]. - There are no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[135]. Business Strategy and Development - The company is focusing on the traditional Chinese medicine sector, leveraging its unique advantages in chronic disease prevention and health management[28]. - The company aims to enhance the quality and innovation of traditional Chinese medicine through new regulatory guidelines and digital transformation initiatives[30]. - The company is focusing on developing a health ecosystem covering prevention, diagnosis, and rehabilitation through three main business segments: traditional Chinese medicine, medical services, and health management[33]. - The company is actively pursuing new product development and market strategies through its various healthcare investments[74]. - The company is developing functional health foods based on the concept of "medicinal food homology," with a focus on high-end nourishing products sourced from Southeast Asia[93]. - The healthcare services segment will focus on a comprehensive life-cycle health management model, integrating prevention, diagnosis, rehabilitation, and health maintenance services[93]. Market and Industry Trends - The national strategy continues to promote the development of traditional Chinese medicine, aiming for a trillion-level health industry by 2030[28]. - The pharmaceutical industry in China achieved a revenue of CNY 29,762.7 billion, remaining flat year-on-year, while profits decreased by 0.9% to CNY 4,050.9 billion[29]. - The traditional Chinese medicine sector saw a decline in revenue and profit by 2.3% and 0.2% respectively[29]. - The company is positioned to benefit from policy incentives and market demand, driving the industry towards standardization and internationalization[28]. Risk Management - The management has highlighted potential risks and corresponding measures in the future development outlook section[5]. - The company faces risks in expanding its healthcare services due to the time required for market cultivation, which may impact short-term profitability[94]. - The company is exposed to risks related to the supply and price volatility of raw materials, particularly Chinese medicinal herbs, which could impact profitability[95]. - The company will strengthen research and analysis of the upstream Chinese medicinal materials market to effectively reduce risks related to raw material supply and price fluctuations[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[102]. - The company has a dedicated audit committee responsible for overseeing internal control systems and the authenticity of financial information[105]. - The company actively engages with investors through various platforms, ensuring transparency and protecting the rights of minority shareholders[103]. - The company has established a comprehensive internal control system to improve governance and operational efficiency[101]. - The company has committed to maintaining a high level of information disclosure, ensuring that all shareholders have equal access to company information[103]. Environmental Responsibility - The company holds a pollution discharge permit valid from August 25, 2023, to August 24, 2028, for various manufacturing activities[142]. - The company complies with the wastewater discharge standards, with CODcr levels at 89 mg/L, which is below the limit of 100 mg/L[143]. - The company has implemented measures to ensure that ammonia nitrogen levels in wastewater do not exceed the standard of 8 mg/L[143]. - The company has not reported any instances of exceeding pollution discharge limits during the reporting period[143]. - The company has invested CNY 523,500 in environmental governance and protection during the reporting period[146]. Employee Management - The company reported a total of 667 employees at the end of the reporting period, with 292 in the parent company and 375 in major subsidiaries[128]. - The employee composition includes 147 production staff, 224 sales personnel, 57 technical staff, 27 financial staff, and 212 administrative staff[128]. - The company has established a performance evaluation system linking employee salaries to company performance and key performance indicators[129]. - The company has conducted training programs focusing on new employee onboarding, GMP training, and management skills development[130]. Investment and Acquisitions - The company invested 680 million yuan to acquire 85% of Guangdong Tongren Pharmaceutical Co., Ltd., enhancing its capabilities in the Chinese herbal medicine and herbal pieces business[43]. - The company acquired 85% of Guangdong Wannianqing Pharmaceutical Co., Ltd. for 6.8 million yuan and has completed the business registration change[137]. - The company also acquired 51% of Hainan Wanmitang Pharmaceutical Co., Ltd. for 1.53 million yuan, but the business registration change has not yet been completed[137]. - The company has cumulatively used CNY 36,970.81 million of the raised funds, representing 84.02% of the total amount raised[81]. Shareholder Relations - The participation rate of investors in the 2024 first extraordinary general meeting was 56.18%[108]. - The participation rate of investors in the 2023 annual general meeting was 56.17%[109]. - The company has a total of 13,167 ordinary shareholders at the end of the reporting period, a decrease from 13,374 at the end of the previous month[200]. - The company has a total of 5 shareholders holding more than 5% of the shares, with the largest shareholder being Guangdong Jino Health Technology Co., Ltd.[200].

证券代码：301111 证券简称：粤万年青 公告编号：2025-014 广东万年青制药股份有限公司 关于使用部分闲置募集资金（含超募资金）和自有资金进行 现金管理到期赎回并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2024 年 12 月 18 日召 开第三届董事会第四次会议及第三届监事会第四次会议，并于 2025 年 1 月 3 日 召开 2025 年第一次临时股东大会，审议通过了《关于使用部分闲置募集资金 （含超募资金）和自有资金进行现金管理的议案》，同意公司在确保不影响正常 运营和募集资金投资项目建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿 元）的闲置募集资金（含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的 自有资金进行现金管理，上述额度自股东大会审议通过之日起 12 个月内有效。 在上述额度和期限范围内，资金可循环滚动使用，并授权公司管理层在额度范 围内行使相关决策权、签署相关合同文件等。具体内容详见公司于 2024 年 12 月 19 日及 ...

广东万年青制药股份有限公司 关于持股5%以上股东减持股份变动触及5%的整数倍及减持 计划期限届满暨实施结果的公告 公司股东合和投资控股（广州）合伙企业（有限合伙）保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2024 年 12 月 16 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东股份减持计划 的预披露公告》 （公告编号：2024-045），股东合和投资控股（广州）合伙企业 （有限合伙）（以下简称"合和投资"）计划自该公告披露之日起十五个交易日 后的三个月内（2025 年 1 月 7 日-2025 年 4 月 6 日）以集中竞价、大宗交易方式 合计减持公司股份不超过4,800,000股，即减持比例不超过公司总股本的3.00%。 公司于 2025 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于 持股 5%以上股东减持股份暨权益变动触及 1%的公告》，合和投资通过集中竞价及 大宗交易 ...

广东万年青制药股份有限公司 简式权益变动报告书 上市公司名称：广东万年青制药股份有限公司 上市地点：深圳证券交易所 股票简称：粤万年青 股票代码：301111 信息披露义务人：合和投资控股（广州）合伙企业（有限合伙） 住所/通讯地址：广州市天河区华强路 3 号之二 2602 房（自编:B7） 股权变动性质：持股比例减少 签署日期：2025 年 4 月 8 日 一、本报告书系信息披露义务人依据《公司法》《证券法》《上市公司收购 管理办法》《证券期货法律适用意见第 19 号—<上市公司收购管理办法>第十三 条、第十四条的适用意见》和《公开发行证券的公司信息披露内容与格式准则第 15 号-权益变动报告书》等相关法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行不违反 信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《上市公司收购管理办法》《公开发行证券的公司信息 披露内容与格式准则第 15 号-权益变动报告书》相关规定，本报告书已全面披露 了信息披露义务人在粤万年青拥有权益的股份变动情况。 截至本报告书签署日，除本报告书披露的信息外，信息披露义务人 ...

Core Insights - The article highlights the successful conclusion of the "Compliance New Journey, Building the Future" private meeting hosted by Yue Wannianqing and Guotou Securities, emphasizing the company's commitment to innovation and its leading position in the traditional Chinese medicine sector [1] Company Overview - Yue Wannianqing, with over 130 years of history, originated from the Shantou Pharmaceutical Factory and has established a strong reputation in drug research, production, and sales [2] - The company adheres to the principles of "innovation, excellence, and quality first," and has developed specialized brands in areas such as gallbladder health, diabetes management, and kidney support [2] - The "Wannianqing" brand was recognized as a "Chinese Time-Honored Brand" in February 2024, reflecting its brand value in the traditional Chinese medicine industry [2] Market Trends - The demand for traditional Chinese medicine (TCM) has been increasing, driven by factors such as an aging population, changes in dietary structure, and environmental pollution [2] - There is a notable shift in disease patterns from infectious to chronic non-communicable diseases, with rising incidences of cardiovascular, respiratory, and endocrine diseases, where TCM shows advantages in treatment [2] Product Development - Yue Wannianqing has developed a diverse product portfolio, including 101 products with national drug approval, covering various forms such as tablets, capsules, and injections [3] - The company has 32 original innovative products, 10 exclusive varieties, and 4 unique dosage forms, with 38 products included in the national medical insurance directory [3] - The company has increased its R&D investment, focusing on product innovation and improvement, and its product "Shenqi Jiangtang Pian" has been selected for national centralized procurement [3][4] Strategic Expansion - To explore new growth opportunities, Yue Wannianqing has extended its business into the health industry chain, acquiring 85% of Guangdong Tongren Pharmaceutical Co., now known as Guangdong Wannianqing Pharmaceutical Co., focusing on the production and trade of Chinese medicinal materials [5] - The company has also invested in the establishment of the Wannianqing International Medical Port, a comprehensive healthcare complex in Shantou, which integrates various medical services and aims to meet diverse healthcare needs in the region [6]

证券代码：301111 证券简称：粤万年青 公告编号：2025-012 关于持股5%以上股东减持股份暨权益变动触及1%的公告 公司股东合和投资控股（广州）合伙企业（有限合伙）保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2024 年 12 月 16 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东股份减持计划 的预披露公告》 （公告编号：2024-045），股东合和投资控股（广州）合伙企业 （有限合伙）（以下简称"合和投资"），计划自该公告披露之日起十五个交易 日后的三个月内（2025 年 1 月 7 日-2025 年 4 月 6 日），以集中竞价、大宗交易 方式合计减持公司股份不超过 4,800,000 股，即减持比例不超过公司总股本的 3.00%。 公司于近日收到合和投资的《关于减持股份触及 1%的告知函》，获悉合和投 资通过集中竞价及大宗交易的方式累计减持公司股份 1,698,000 股，占公司总股 本的比例为 ...

北京· 上海· 深圳· 杭州· 广州· 昆明· 天津· 成都· 宁波· 福州· 西安· 南京· 南宁· 济南· 重庆· 苏州· 长沙· 太原· 武汉· 贵阳 乌鲁木齐· 郑州· 石家庄· 合肥· 海南· 青岛· 南昌· 大连· 银川· 拉孜· 香港· 巴黎· 马德里· 斯德哥尔摩· 纽约· 马来西亚 广州市天河区华夏路 32 号太平洋金融大厦 19 楼 邮编：510620 电话：(+86)(20) 3879 9346 、38799348 传真：(+86)(20) 3879 9348-200 国浩律师(广州)事务所 关于广东万年青制药股份有限公司 2025 年第二次临时股东大会的法律意见 广东万年青制药股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受广 东万年青制药股份有限公司(以下简称"万年青")的委托，指派郭佳、林嘉豪律 师(以下简称"本所律师")出席万年青 2025 年第二次临时股东大会(以下简称 "本次股东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集 人的资格、表决程序与表决结果等 ...

广东万年青制药股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 证券代码：301111 证券简称：粤万年青 公告编号：2025-010 （1）现场会议召开时间：2025 年 2 月 12 日下午 15:00 （2）网络投票时间：深圳证券交易所（"深交所"）交易系统投票时间为： 2025 年 2 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00；深交所互联网投票系 统投票时间为：2025 年 2 月 12 日 9:15-15:00。 2、现场会议召开地点：广东省汕头市长平路 94 号万年青国际医疗港会议室 3、会议召集人：董事会 4、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式。 5、会议主持人：董事长欧先涛先生 6. 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东大 会规则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门 规章、规范性文件和《广东万年青制药股份有限公司章程》（以下简称 ...

广东万年青制药股份有限公司 第三届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 2 月 12 日在 公司会议室以现场表决方式召开公司第三届监事会第六次会议，为保证监事会工 作的连续性，会议于 2025 年 2 月 12 日在公司 2025 年第二次临时股东大会补选 第三届监事会非职工代表监事成员后，经全体监事同意豁免会议通知时间要求， 于 2025 年 2 月 12 日现场向全体监事发出会议通知。本次会议由全体监事共同推 举监事谢维鑫先生主持，本次会议应出席的监事 3 名，实际出席的监事 3 名。公 司董事会秘书列席了本次会议。 本次监事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律、法规及《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议，形成以下决议： （一）审议通过了《关于选举公司第三届监事会主席的议案》 证券代码：301111 证券简称：粤万年青 公告编号：2025-011 ...